Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain ...

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

Merck & Co Inc. (NYSE:MRK) is one of the best stocks to invest in, according to billionaire D.E. Shaw. On October 30, Merck & ...

Merck & Co. is taking full control of MK-8690, an investigational drug targeting inflammatory bowel diseases that was part of the drugmaker's $10.8 billion acquisition of Prometheus Biosciences in ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Wondering if Merck stock is truly a bargain or just priced for perfection? You are not alone. Let's dig into what the numbers ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

Discover Merck & Co., Inc.'s Q3 earnings outlook as Keytruda's patent nears expiry. Click for my updated look at MRK stock ...

AstraZeneca, Eli Lilly and Merck committed $120 million to develop an advanced pharmaceutical manufacturing training center in Central Virginia.